AbbVie's promising oral hepatitis C combo treatment is rolling along toward FDA approval, and the drugmaker unveiled a deeper set of Phase III data in which the cocktail cured nearly 100% of patients in a tough-to-treat population.
As the biosimilar market takes shape, companies are gunning to produce copies of some of the world's top-selling drugs. And according to a new Moody's report, with their star products wearing targets on their backs, AbbVie, Amgen and Roche are most exposed to the new competition.
Right on schedule, Gilead Sciences has submitted its combination hepatitis C treatment for FDA approval, inching toward the era of interferon-free treatment and widening its lead on rival AbbVie.
Five days after the FDA announced it would investigate the heart and stroke dangers of testosterone-enhancing drugs, 5 lawsuits were filed against Abbott Laboratories and its spinoff AbbVie by men who claimed they suffered heart attacks or strokes after using one of those products, AndroGel.
Humira, the best-selling drug in the world, continues to power the top and bottom lines for the year-old pharma spinoff AbbVie. But the drugmaker has a pipeline of new products it is looking to get approved, and for that it says it needs some more production capacity.
Singapore has become a biopharma manufacturing hub, drawing the likes of Novartis, GlaxoSmithKline and Amgen. Even Russia's Pharmstandard has an API facility there. Now AbbVie will join the group.
The National Institutes of Health has persuaded 10 rival drugmakers to briefly set aside their competitive spirits and collaborate on drug discovery projects in four major diseases, pooling their data and expertise to kick-start early-stage efforts.
AbbVie's first full year as an independent pharma company is on the books, and the fast-growing drug that has buoyed it from the start continues to churn out sales growth. Once again, Humira revenues made double-digit gains, driving a fourth-quarter profit that matched analysts' expectations.
AbbVie has wrapped up its late-stage studies of a promising interferon-free hepatitis C cocktail, setting the stage for near-term FDA application and a showdown with rival Gilead Sciences.
Abbott's diagnostics sales soared during the 2013 fourth quarter and medical device numbers also grew at a moderate clip. As well, emerging-market sales climbed strongly. But net earnings plunged, without the Illinois company's old pharmaceutical business to prop things up.